Target Validation Information
TTD ID T58992
Target Name Opioid receptor delta (OPRD1)
Type of Target
Successful
Drug Potency against Target Butorphanol Drug Info Ki = 0.5 nM [91]
Codeine Drug Info Ki > 1000 nM
Hydrocodone Drug Info Ki = 1021 nM
Loperamide Drug Info IC50 = 6.9 nM [92]
Nalbuphine Drug Info Ki = 1.4 nM [91]
BIO-306 Drug Info IC50 = 130 nM [93]
Drug Info Ki = 70 nM [2]
Drug Info IC50 = 6.9 nM [62]
(-)-cyclorphan Drug Info Ki = 1.9 nM [10]
(-)-eseroline Drug Info IC50 = 10000 nM
(-)-isoelaeocarpiline Drug Info IC50 = 9900 nM [24]
(H-Dmt-Tic-Glu-NH-(CH(2))(5)-CO-Dap(6DMN)-NH(2) Drug Info Ki = 0.158 nM [15]
1,10-bis-(Dmt-Tic-amino)decane Drug Info Ki = 1.53 nM [8]
1,4-bis-(Dmt-Tic-amino)butane Drug Info Ki = 0.124 nM [8]
1,6-bis-(Dmt-Tic-amino)hexane Drug Info Ki = 0.129 nM [8]
1-(1,2-diphenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 187 nM [33]
1-(2-ethoxy-1-phenylethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 15250 nM [33]
1-(dio-tolylmethyl)-4-phenylpiperidin-4-ol Drug Info Ki = 5791 nM [33]
1-benzhydryl-4-(2-fluorophenyl)piperidin-4-ol Drug Info Ki = 5610 nM [32]
1-benzhydryl-4-(2-methoxyphenyl)piperidin-4-ol Drug Info Ki = 4392 nM [32]
1-benzhydryl-4-(3-fluorophenyl)piperidin-4-ol Drug Info Ki = 5610 nM [32]
1-benzhydryl-4-(3-methoxyphenyl)piperidin-4-ol Drug Info Ki = 9585 nM [32]
1-benzhydryl-4-(3-phenylpropyl)piperidin-4-ol Drug Info Ki = 13750 nM [32]
1-benzhydryl-4-(4-bromophenyl)piperidin-4-ol Drug Info Ki = 15240 nM [32]
1-benzhydryl-4-(4-chlorophenyl)piperidin-4-ol Drug Info Ki = 6364 nM [32]
1-benzhydryl-4-(4-fluorophenyl)piperidin-4-ol Drug Info Ki = 3325 nM [32]
1-benzhydryl-4-(4-methoxyphenyl)piperidin-4-ol Drug Info Ki = 19220 nM [32]
1-benzhydryl-4-(benzyloxy)-4-phenylpiperidine Drug Info Ki = 3741 nM [33]
1-benzhydryl-4-(furan-2-yl)piperidin-4-ol Drug Info Ki = 14455 nM [32]
1-benzhydryl-4-(thiophen-2-yl)piperidin-4-ol Drug Info Ki = 8446 nM [32]
1-benzhydryl-4-benzylpiperidin-4-ol Drug Info Ki = 15010 nM [32]
1-benzhydryl-4-butylpiperidin-4-ol Drug Info Ki = 18800 nM [32]
1-benzhydryl-4-cyclohexylpiperidin-4-ol Drug Info Ki = 8105 nM [32]
1-benzhydryl-4-ethoxy-4-phenylpiperidine Drug Info Ki = 898 nM [33]
1-benzhydryl-4-hexylpiperidin-4-ol Drug Info Ki = 17865 nM [32]
1-benzhydryl-4-m-tolylpiperidin-4-ol Drug Info Ki = 7796 nM [32]
1-benzhydryl-4-methoxy-4-phenylpiperidine Drug Info Ki = 2651 nM [33]
1-benzhydryl-4-o-tolylpiperidin-4-ol Drug Info Ki = 1668 nM [32]
1-benzhydryl-4-p-tolylpiperidin-4-ol Drug Info Ki = 12115 nM [32]
1-benzhydryl-4-phenyl-4-propoxypiperidine Drug Info Ki = 2767 nM [33]
1-benzhydryl-4-phenylpiperidin-4-ol Drug Info Ki = 1666 nM [63]
1-[3-(4-biphenyl)-(1,2,4-triazol-4-yl) ]-3-phenol Drug Info Ki = 1500 nM [17]
14-O-phenylpropylnaltrexone Drug Info Ki = 0.48 nM [61]
17-(Cyclobutylmethyl)-N-phenylmorphinan-3-amine Drug Info Ki = 39 nM [73]
17-(Cyclopropylmethyl)-N-phenylmorphinan-3-amine Drug Info Ki = 5.4 nM [73]
17-methyl-4'-methyldihydromorphinone Drug Info Ki = 4 nM [19]
17-Methylmorphinan-3-yl 4-Iodophenyl Carbamate Drug Info Ki = 160 nM [73]
2-Hydroxymethyl-3-hydroxymorphinan Drug Info Ki = 1400 nM [73]
3,6-bis(Dmt-Tic-NH-butyl)-2(1H)-pyrazinone Drug Info Ki = 0.323 nM [8]
3,6-bis(Dmt-Tic-NH-methyl)-2(1H)-pyrazinone Drug Info Ki = 0.163 nM [8]
3,6-bis(Dmt-Tic-NH-propyl)-2(1H)-pyrazinone Drug Info Ki = 0.155 nM [8]
3-desoxy-3-carboxamidonaltrexone Drug Info Ki = 550 nM [62]
4-(4-((phenethylamino)methyl)phenoxy)benzamide Drug Info Ki = 1.88 nM [40]
4-(p-Tolyl)spiro[chromene-2,4'-piperidine] Drug Info Ki = 72 nM [56]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)benzamide Drug Info Ki = 17 nM [68]
4-(Spiro[chromene-2,4'-piperidine]-4-yl)phenol Drug Info Ki = 59 nM [56]
4-phenyl-1-(1-phenylbutyl)piperidin-4-ol Drug Info Ki = 4126 nM [33]
4-phenyl-1-(1-phenylheptyl)piperidin-4-ol Drug Info Ki = 550 nM [33]
4-phenyl-1-(1-phenylhexyl)piperidin-4-ol Drug Info Ki = 184 nM [33]
4-phenyl-1-(1-phenylpentyl)piperidin-4-ol Drug Info Ki = 441 nM [33]
4-phenyl-1-(phenyl(m-tolyl)methyl)piperidin-4-ol Drug Info Ki = 2437 nM [33]
4-phenyl-1-(phenyl(p-tolyl)methyl)piperidin-4-ol Drug Info Ki = 9365 nM [33]
4-phenyl-4-[1H-imidazol-2-yl]-piperidine Drug Info Ki = 81 nM [7]
4-Phenylspiro[chromene-2,4'-piperidine] Drug Info Ki = 71 nM [56]
5-(4-((phenethylamino)methyl)phenoxy)picolinamide Drug Info Ki = 8.54 nM [40]
6-(2-phenethylisoindolin-5-yloxy)nicotinamide Drug Info Ki = 2274 nM [43]
6-(4-((benzylamino)methyl)phenoxy)nicotinamide Drug Info Ki = 54.15 nM [40]
6-(4-((phenethylamino)methyl)phenoxy)nicotinamide Drug Info Ki = 1.16 nM [43]
6-(4-(2-(benzylamino)ethyl)phenoxy)nicotinamide Drug Info Ki = 70.21 nM [43]
6-(4-(3-(benzylamino)propyl)phenoxy)nicotinamide Drug Info Ki = 495.99 nM [40]
6-(Allyl-methyl-amino)-4,4-diphenyl-heptan-3-ol Drug Info Ki = 150 nM [84]
6-cinnamoyl-N-methylstephasunoline Drug Info IC50 = 11300 nM [77]
6-cinnamoylhernandine Drug Info IC50 = 5100 nM [77]
6-desoxonaltrexone Drug Info Ki = 79 nM [62]
6beta-naltrexol HCl Drug Info Ki = 213 nM [65]
8-azabicyclo[3.2.1]octan-3-yloxy-benzamide Drug Info IC50 = 8306 nM [80]
8-carboxamidocyclazocine Drug Info Ki = 5.2 nM [52]
AIKO-150 Drug Info Ki = 53 nM [59]
AKNADILACTAM Drug Info IC50 = 17000 nM [77]
AMINOFENTANYL Drug Info IC50 = 13000 nM [18]
ANALOG OF DYNORPHIN A Drug Info IC50 = 9.1 nM [86]
Antanal 1 Drug Info Ki = 17.4 nM [57]
Antanal 2 Drug Info Ki = 7.74 nM [57]
Benzyl derivative of M6G Drug Info Ki = 7.2 nM [4]
BIPHALIN Drug Info IC50 = 2.7 nM [69]
Bis-((-)-N-propargylmorphinan-3-yl) sebacoylate Drug Info Ki = 190 nM [10]
BUTORPHAN Drug Info Ki = 5.9 nM [75]
CARBOXYFENTANYL Drug Info Ki = 9400 nM [42]
Cis-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 0.59 nM [38]
Clocinnamox Drug Info Ki = 2.7 nM [61]
CTOP Drug Info IC50 = 13500 nM [57]
CYCLAZOCINE Drug Info Ki = 2 nM [60]
CYCLORPHAN Drug Info Ki = 1.9 nM [73]
C[L-mTyr-D-pro-L-Phe-D-trp] Drug Info Ki = 670 nM [66]
C[L-Phe-D-pro-L-mTyr-D-trp] Drug Info Ki = 3400 nM [66]
C[L-Phe-D-pro-L-Phe-L-trp] Drug Info Ki = 2000 nM [66]
D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2(CTAP) Drug Info IC50 = 4500 nM [83]
D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2(CTP) Drug Info IC50 = 8400 nM [83]
D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2(CTOP) Drug Info IC50 = 13500 nM [83]
D-PhGly-Cys-Tyr-D-Trp-Lys-Thr-Pen-Thr-NH2 Drug Info IC50 = 2800 nM [83]
DADLE Drug Info IC50 = 0.27 nM [37]
DAMGO Drug Info Ki = 2670 nM
Dcp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Drug Info Ki = 25.8 nM [20]
DELTORPHIN-II Drug Info IC50 = 0.53 nM [78]
Deprotected cogener of M6G Drug Info Ki = 266.3 nM [4]
DERMORPHIN Drug Info IC50 = 15.2 nM [9]
Dhp-c[D-Cys-Gly-Phe(pNO2)-D-Cys]NH2 Drug Info Ki = 11.6 nM [20]
Dimepheptanol Drug Info Ki = 230 nM [84]
Dmt-Pro-3,5Dmp-Phe-NH2 Drug Info Ki = 11.6 nM [36]
Dmt-Pro-Dmp-Phe-NH2 Drug Info Ki = 2.27 nM [36]
Dmt-Pro-Dmt-Phe-NH2 Drug Info Ki = 80.8 nM [36]
Dmt-Pro-Emp-Phe-NH2 Drug Info IC50 = 0.51 nM [36]
Dmt-Pro-Imp-Phe-NH2 Drug Info IC50 = 5.56 nM [36]
Dmt-Pro-Mmp-Phe-NH2 Drug Info Ki = 4.61 nM [36]
Dmt-Pro-Phe-D-1-Nal-NH2 Drug Info Ki = 27.1 nM [28]
Dmt-Pro-Phe-D-2-Nal-NH2 Drug Info Ki = 7.74 nM [28]
Dmt-Pro-Phe-Phe-NH2 Drug Info IC50 = 0.59 nM [36]
Dmt-Pro-Tmp-Phe-NH2 Drug Info Ki = 1.83 nM [36]
Dmt-Pro-Trp-D-2-Nal-NH2 Drug Info Ki = 17.4 nM [28]
DPDPE Drug Info Ki = 2.72 nM
ELAEOCARPENINE Drug Info Ki = 14000 nM [74]
ENDOMORPHIN 2 Drug Info IC50 = 510 nM [79]
ENDOMORPHIN-1 Drug Info Ki = 1909 nM [54]
ETONITAZENE Drug Info Ki = 0.6 nM [82]
FALCARINDIOL Drug Info Ki = 1096 nM [46]
Grandisine C Drug Info IC50 = 14600 nM [24]
Grandisine D Drug Info IC50 = 1650 nM [24]
Grandisine F Drug Info IC50 = 1550 nM [24]
H-2',6'-dimethyltyrosine-Tic-OH Drug Info Ki = 1.84 nM [71]
H-2',6'-dimethyltyrosine-Tic-Phe-Phe-OH Drug Info Ki = 0.248 nM [71]
H-Aba-ala-Gly-Phe-leu-OH Drug Info Ki = 10 nM [31]
H-Aba-ala-Gly-Phe-Met-OH Drug Info Ki = 1 nM [31]
H-Aba-Gly-Gly-Phe-Leu-OH Drug Info Ki = 19 nM [31]
H-Aba-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 3.8 nM [31]
H-Apa-ala-Gly-Phe-leu-OH Drug Info Ki = 19 nM [31]
H-Cdp-ala-Gly-Phe-leu-OH Drug Info Ki = 0.78 nM [31]
H-Cdp-Gly-Gly-Phe-Leu-OH Drug Info Ki = 1 nM [31]
H-Cdp-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 1.2 nM [31]
H-Cpa-c[pen-Gly-Phe-pen]OH Drug Info Ki = 19 nM [31]
H-Cpa-Gly-Gly-Phe-Met-NH2 Drug Info Ki = 1.3 nM [31]
H-Cpa-Gly-Gly-Phe-Met-OH Drug Info Ki = 1.8 nM [31]
H-Cxp-ala-Gly-Phe-leu-OH Drug Info Ki = 1100 nM [31]
H-D-Tca-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 211 nM [1]
H-D-Tic-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 1270 nM [1]
H-D-Trp-c[Cys-Tyr-D-Trp-Arg-Thr-Pen]-Thr-NH2 Drug Info IC50 = 3530 nM [1]
H-Dmt-Aba-Gly-NH-CH2-Bid Drug Info IC50 = 2700 nM [16]
H-Dmt-Aba-Gly-NH-CH2-Ph Drug Info IC50 = 830 nM [16]
H-Dmt-Aba-Gly-NH-Ph Drug Info IC50 = 650 nM [16]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-NH2 Drug Info IC50 = 1.69 nM [5]
H-Dmt-D-Arg(NO2)-Phe-Lys(Z)-OH Drug Info IC50 = 682 nM [5]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-NH2 Drug Info Ki = 13 nM [27]
H-Dmt-Tic-(2R,3R)-beta-MeCha-Phe-OH Drug Info Ki = 2 nM [27]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-NH2 Drug Info Ki = 7 nM [27]
H-Dmt-Tic-(2R,3S)-beta-MeCha-Phe-OH Drug Info Ki = 1.5 nM [27]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-NH2 Drug Info Ki = 4.1 nM [27]
H-Dmt-Tic-(2S,3R)-beta-MeCha-Phe-OH Drug Info Ki = 2 nM [27]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-NH2 Drug Info Ki = 4 nM [27]
H-Dmt-Tic-(2S,3S)-beta-MeCha-Phe-OH Drug Info Ki = 0.48 nM [27]
H-Dmt-Tic-Asp-N(Me)-Ph Drug Info Ki = 0.186 nM [55]
H-Dmt-Tic-Asp-NH-Ph Drug Info IC50 = 265 nM [55]
H-Dmt-Tic-D-Asp-NH-Ph Drug Info IC50 = 2655 nM [55]
H-Dmt-Tic-Glu-Dap(6DMN)-NH(2) Drug Info Ki = 7.8 nM [15]
H-Dmt-Tic-Glu-NH-(CH2)5-NH2 Drug Info Ki = 0.22 nM [3]
H-Dmt-Tic-Glu-NH2 Drug Info IC50 = 2.58 nM [3]
H-Dmt-Tic-Gly-N(Me)-Ph Drug Info IC50 = 1466 nM [55]
H-Dmt-Tic-Gly-NH-Bzl Drug Info IC50 = 2.69 nM [55]
H-Dmt-Tic-Gly-NH-CH2-Bid Drug Info IC50 = 0.13 nM [16]
H-Dmt-Tic-Gly-NH-Ph Drug Info IC50 = 2.57 nM [55]
H-Dmt-Tic-Lys(Ac)-NH-Ph Drug Info Ki = 0.13 nM [22]
H-Dmt-Tic-Lys(Z)-NH-CH2-Ph Drug Info Ki = 0.31 nM [22]
H-Dmt-Tic-Lys(Z)-NH-Ph Drug Info Ki = 0.57 nM [22]
H-Dmt-Tic-Lys-NH-CH2-Ph Drug Info Ki = 0.5 nM [22]
H-Dmt-Tic-Lys-NH-Ph Drug Info Ki = 0.42 nM [22]
H-Dmt-Tic-NH-(CH2)6-NH-Dmt-H Drug Info Ki = 0.23 nM [6]
H-Dmt-Tic-NH-(CH2)6-NH-Phe-H Drug Info Ki = 0.89 nM [6]
H-Dmt-Tic-NH-(CH2)6-NH-Tic-H Drug Info Ki = 0.13 nM [6]
H-Dmt-Tic-NH-(D)-CH[(CH2)4-NH-Z]-Bid Drug Info Ki = 0.4 nM [22]
H-Dmt-Tic-NH-(R)CH(CH2-COOH)-Bid Drug Info IC50 = 179 nM [55]
H-Dmt-Tic-NH-(S)CH(CH2-COOH)-Bid(N1-Me) Drug Info IC50 = 2886 nM [55]
H-Dmt-Tic-NH-CH2-Boa Drug Info Ki = 0.283 nM [47]
H-Dmt-Tic-NH-CH2-Bta Drug Info Ki = 0.145 nM [47]
H-Dmt-Tic-NH-CH2-CH2-NH2 Drug Info Ki = 1.81 nM [41]
H-Dmt-Tic-NH-CH2-Imid Drug Info IC50 = 3.63 nM [47]
H-Dmt-Tic-NH-CH2-ImidPh Drug Info Ki = 0.443 nM [47]
H-Dmt-Tic-NH-CH2-Indn Drug Info IC50 = 129 nM [47]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Ac]-Bid Drug Info Ki = 0.18 nM [22]
H-Dmt-Tic-NH-CH[(CH2)4-NH-Z]-Bid Drug Info IC50 = 9049 nM [22]
H-Dmt-Tic-NH-CH[(CH2)4-NH2]-Bid Drug Info Ki = 0.49 nM [22]
H-mCpa-ala-Gly-Phe-leu-OH Drug Info Ki = 170 nM [31]
H-mCpa-Gly-Gly-Phe-Leu-OH Drug Info Ki = 475 nM [31]
H-mCpa-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 42 nM [31]
H-Poa-ser-Gly-Phe-Leu-Thr-OH Drug Info Ki = 360 nM [31]
H-Tyr-c[cys-Gly-Phe(p-NO2)-cys]NH2 Drug Info IC50 = 0.232 nM [31]
H-Tyr-c[D-Allylgly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 3.4 nM [38]
H-Tyr-c[D-Cys-Gly-Phe-D-Cys]NH2 Drug Info Ki = 0.822 nM [30]
H-Tyr-c[D-Cys-Gly-Phe-L-Cys]NH2 Drug Info Ki = 1.61 nM [30]
H-Tyr-c[D-Orn-(D or L)Atc-Glu]-NH2 Drug Info Ki = 3510 nM [12]
H-Tyr-c[D-Orn-Aic-Glu]-NH2 Drug Info Ki = 209 nM [12]
H-Tyr-c[pen-Gly-Phe-pen]OH Drug Info Ki = 3.2 nM [31]
H-Tyr-D-Ala-Gly Phe-Pro-Leu-Trp-O-3,5-Bzl(CF3)2 Drug Info IC50 = 400 nM [48]
H-Tyr-D-Ala-Gly-Phe-NH-NH-(NMe)Phe-Asp-Nle-Trp-Ac Drug Info IC50 = 5.1 nM [11]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Phe-D-Asp-D-Nle-Trp-H Drug Info IC50 = 15 nM [26]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-Bo Drug Info IC50 = 16 nM [26]
H-Tyr-D-Ala-Gly-Phe-NH-NH-D-Trp-Nle-Asp-Phe-H Drug Info IC50 = 12 nM [26]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-Boc Drug Info IC50 = 24 nM [11]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-D-Trp-H Drug Info IC50 = 26 nM [11]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Ac Drug Info IC50 = 36 nM [11]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-Nle-Trp-Boc Drug Info IC50 = 230 nM [11]
H-Tyr-D-Ala-Gly-Phe-NH-NH-Trp-D-Nle-D-Asp-D-Phe-H Drug Info IC50 = 25 nM [26]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-3,5-Bzl(CF3)2 Drug Info IC50 = 45 nM [48]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NH-Bzl Drug Info IC50 = 50 nM [48]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-3,5-Bzl(CF3)2 Drug Info IC50 = 150 nM [48]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-NMe-Bzl Drug Info IC50 = 41 nM [48]
H-Tyr-D-Ala-Gly-Phe-Pro-Leu-Trp-O-Bzl Drug Info IC50 = 40 nM [48]
H-Tyr-Gly-Gly-Phe-Met-NH2 Drug Info Ki = 10 nM [31]
H-Tyr-NMe-D-Ala-Phe-Sar-NH2 Drug Info IC50 = 7100 nM [49]
H-Tyr-Pro-Dap(6DMN)-Phe-NH2 Drug Info IC50 = 500 nM [15]
H-Tyr-Pro-Phe-Phe-NH-(CH2)5-(C=O)-Dap(6DMN)-NH2 Drug Info IC50 = 300 nM [15]
H-Tyr-Pro-Phe-Phe-NH-CH2-CH2-NH Tic Dmt-H Drug Info Ki = 1.45 nM [41]
H-Tyr-Tic-Cha-Phe-OH Drug Info Ki = 0.61 nM [27]
H-Tyr-Tic-OH Drug Info Ki = 242 nM [71]
HERKINORIN Drug Info Ki = 1170 nM [50]
HTyr-Gly-Gly-Phe-Leu-Arg-Arg-lle-Arg-Pro-LysNH2 Drug Info Ki = 6.18 nM [70]
ICI-174864 Drug Info IC50 = 83 nM [21]
Isoelaeocarpine Drug Info IC50 = 13600 nM [35]
LOFENTANIL Drug Info IC50 = 0.25 nM [85]
LONGANINE Drug Info IC50 = 700 nM [77]
LY-25582 Drug Info Ki = 198 nM [90]
M6G thiosaccharide analogue Drug Info Ki = 31.4 nM [4]
MC-CAM Drug Info Ki = 4.79 nM [72]
MCL-117 Drug Info Ki = 0.62 nM [10]
MCL-139 Drug Info Ki = 9.4 nM [10]
MCL-144 Drug Info Ki = 4.2 nM [67]
MCL-145 Drug Info Ki = 9.4 nM [10]
MCL-147 Drug Info Ki = 29 nM [34]
MCL-149 Drug Info Ki = 150 nM [34]
MCL-153 Drug Info Ki = 730 nM [75]
MCL-154 Drug Info Ki = 2500 nM [75]
MCL-182 Drug Info Ki = 180 nM [34]
MCL-183 Drug Info Ki = 230 nM [34]
MCL-428 Drug Info Ki = 3.9 nM [29]
MCL-429 Drug Info Ki = 1.6 nM [29]
MCL-431 Drug Info Ki = 78 nM [29]
MCL-432 Drug Info Ki = 27 nM [29]
MCL-433 Drug Info Ki = 53 nM [29]
MCL-434 Drug Info Ki = 42 nM [29]
MCL-435 Drug Info Ki = 30 nM [29]
MCL-443 Drug Info Ki = 15 nM [29]
MCL-444 Drug Info Ki = 2.7 nM [29]
MCL-445 Drug Info Ki = 270 nM [34]
MCL-446 Drug Info Ki = 50 nM [34]
MCL-447 Drug Info Ki = 160 nM [34]
MCL-448 Drug Info Ki = 23 nM [34]
MCL-449 Drug Info Ki = 2.8 nM [29]
MCL-450 Drug Info IC50 = 3.9 nM [23]
MCL-451 Drug Info IC50 = 10 nM [23]
MCL-458 Drug Info Ki = 360 nM [34]
Met-enkephalin Drug Info Ki = 2 nM [31]
METAZOCINE Drug Info Ki = 140 nM [59]
N-(17-Methylmorphinan-3-yl)-N'-phenylurea Drug Info Ki = 320 nM [73]
N-(4-Iodophenyl)-N'-(17-methylmorphinan-3-yl)urea Drug Info Ki = 300 nM [73]
N-alpha-amidino-Tyr(Me)-Pro-Trp-p-Cl-Phe-NH2 Drug Info IC50 = 1288 nM [25]
N-alpha-amidino-Tyr(Me)-Pro-Trp-Phe-NH2 Drug Info IC50 = 1343 nM [25]
N-Benzyl-17-(cyclobutylmethyl)morphinan-3-amine Drug Info Ki = 130 nM [73]
N-Benzyl-17-(cyclopropylmethyl)morphinan-3-amine Drug Info Ki = 29 nM [73]
N-methylstephisoferulin Drug Info IC50 = 2500 nM [77]
N-methylstephuline Drug Info IC50 = 2100 nM [77]
Naltrexone-6-alpha-ol Drug Info Ki = 56 nM [59]
NORBINALTORPHIMINE Drug Info Ki = 86 nM [2]
O-DESMETHYL TRAMADOL Drug Info Ki = 2900 nM [59]
OXYMORPHINDOLE Drug Info Ki = 0.8 nM [51]
PERIPENTADENINE Drug Info IC50 = 11400 nM [44]
PHENAZOCINE Drug Info Ki = 5 nM [59]
PROSTEPHABYSSINE Drug Info IC50 = 5500 nM [77]
RTI-5989-23 Drug Info Ki = 168 nM [90]
RTI-5989-25 Drug Info Ki = 142 nM [90]
RTI-5989-31 Drug Info Ki = 270 nM [39]
SALVINORIN A Drug Info Ki = 3990 nM [50]
SB-0304 Drug Info IC50 = 17800 nM [49]
SB-213698 Drug Info Ki = 1.44 nM [64]
SN-11 Drug Info Ki = 0.19 nM [64]
SN-23 Drug Info Ki = 0.19 nM [64]
SN-28 Drug Info Ki = 0.14 nM [81]
SNF-9007 Drug Info IC50 = 29 nM [14]
SOMATOSTATIN Drug Info IC50 = 2000 nM [83]
Trans-H-Tyr-c[D-AllylGly-Gly-Phe-D-Allylgly]-OH Drug Info IC50 = 0.76 nM [38]
Tyr-(NMe)Ala-L-Phe-D-Pro-NH2 Drug Info IC50 = 202 nM [88]
Tyr-(R)-Aba-Gly-Phe-NH2 Drug Info Ki = 2.965 nM [45]
Tyr-(S)-Aba-Gly-Phe-NH2 Drug Info Ki = 0.778 nM [45]
Tyr-(S)-spiro-Aba-Gly-Phe-NH2 Drug Info Ki = 2.312 nM [45]
Tyr-D-Ala-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 1300 nM [14]
Tyr-D-Ala-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 63 nM [14]
Tyr-D-Ala-Gly-Phe-Met-NH2 Drug Info IC50 = 36 nM [69]
Tyr-D-Ala-Gly-Phe-Met-Pro-Leu-Trp-NH-Bzl Drug Info IC50 = 4.8 nM [58]
Tyr-D-Ala-Gly-Phe-NH-NH-Phe-Asp-NMeNle-D-Trp-Boc Drug Info IC50 = 42 nM [11]
Tyr-D-Ala-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 45 nM [14]
Tyr-D-Ala-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 66 nM [14]
Tyr-D-Ala-Phe-Asp-Val-Val-Thr[Beta-D-Glc]-Gly-NH2 Drug Info Ki = 1.55 nM [89]
Tyr-D-Ala-Phe-Glu-Val-Val-Gly-NH2 Drug Info IC50 = 0.67 nM [87]
Tyr-D-Ala-Phe-Gly-Tyr-Pro-Thr(Beta-D-Glc)-Gly-NH2 Drug Info Ki = 67 nM [89]
Tyr-D-Ala-Phe-Thr(-D-Glc)-Tyr-Pro-Ser-NH2 Drug Info Ki = 1760 nM [89]
Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 Drug Info IC50 = 0.28 nM [87]
Tyr-D-Nle-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 310 nM [14]
Tyr-D-Nle-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 700 nM [14]
Tyr-D-Nle-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 23 nM [14]
Tyr-D-Nle-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 9 nM [14]
Tyr-D-Phe-Gly-D-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 170 nM [14]
Tyr-D-Phe-Gly-D-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 24 nM [14]
Tyr-D-Phe-Gly-Trp-Nle-Asp-Phe-NH2 Drug Info IC50 = 12 nM [14]
Tyr-D-Phe-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 65 nM [14]
Tyr-D-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 890 nM [14]
Tyr-Gly-Gly-Phe-c(Cys-Arg-Arg-Ile-Cys)-Arg-lys Drug Info IC50 = 6262 nM [86]
Tyr-Gly-Gly-Phe-leu-c(Cys-Arg-Ile-Arg-Cys)-lys Drug Info IC50 = 92.6 nM [86]
Tyr-Gly-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info IC50 = 220 nM [14]
Tyr-Pro-3,5Dmp-Phe-NH2 Drug Info Ki = 3451 nM [36]
Tyr-Pro-D-Phe-D-Pro-NH2 Drug Info IC50 = 4810 nM [88]
Tyr-Pro-D-Phe-Pro-NH2 Drug Info IC50 = 594 nM [88]
Tyr-Pro-D-Phg-Phe-NH2 Drug Info Ki = 2100 nM [13]
Tyr-Pro-Dmp-Phe-NH2 Drug Info IC50 = 1.39 nM [36]
Tyr-Pro-Dmt-Phe-NH2 Drug Info IC50 = 978 nM [36]
Tyr-Pro-Emp-Phe-NH2 Drug Info IC50 = 277 nM [36]
Tyr-Pro-Gly-Trp-NMeNle-Asp-Phe-NH2 Drug Info Ki = 1500 nM [14]
Tyr-Pro-Imp-Phe-NH2 Drug Info Ki = 543 nM [36]
Tyr-Pro-L-(NMe)Phe-D-Pro-NH2 Drug Info IC50 = 1250 nM [88]
Tyr-Pro-L-(NMe)Phe-Pro-NH2 Drug Info IC50 = 1790 nM [88]
Tyr-Pro-L-Phe-D-Pro-NH2 Drug Info IC50 = 1508 nM [88]
Tyr-Pro-L-Phe-Pro-NH2 Drug Info IC50 = 3690 nM [88]
Tyr-Pro-Mmp-Phe-NH Drug Info IC50 = 15.7 nM [36]
Tyr-Pro-Phe-Phe-N(CH3)2 Drug Info IC50 = 2723 nM [53]
Tyr-Pro-Phe-Phe-NHCH3 Drug Info Ki = 8474 nM [53]
Tyr-Pro-Phe-Phe-NHNH2 Drug Info IC50 = 185 nM [53]
Tyr-Pro-Phe-Phe-OC(CH3)3 Drug Info Ki = 247 nM [53]
Tyr-Pro-Phe-Phe-OCH2CH3 Drug Info Ki = 2940 nM [53]
Tyr-Pro-Phe-Phe-OCH2OH Drug Info IC50 = 29.17 nM [53]
Tyr-Pro-Phe-Phe-OCH3 Drug Info IC50 = 37.2 nM [53]
Tyr-Pro-Tmp-Phe-NH Drug Info Ki = 1358 nM [36]
UFP-502 Drug Info IC50 = 0.13 nM [78]
UFP-512 Drug Info IC50 = 0.12 nM [78]
[Dcp1]Dyn A(1-11)-NH2 Drug Info Ki = 129 nM [20]
[Leu5]enkephalin Drug Info Ki = 2.53 nM [76]
Action against Disease Model Butorphanol Drug Info HEK-delta Cells IC50: 61 nM
Hydromorphone Drug Info HEK-deltaCells IC50: 54 nM
Nalbuphine Drug Info HEK-delta Cells IC50: 545 nM
References
REF 1 Opiate aromatic pharmacophore structure-activity relationships in CTAP analogues determined by topographical bias, two-dimensional NMR, and biologi... J Med Chem. 2000 Feb 24;43(4):569-80.
REF 2 Identification of (3R)-7-hydroxy-N-((1S)-1-[[(3R,4R)-4-(3-hydroxyphenyl)- 3,4-dimethyl-1-piperidinyl]methyl]-2-methylpropyl)-1,2,3,4-tetrahydro- 3-... J Med Chem. 2003 Jul 3;46(14):3127-37.
REF 3 Highly selective fluorescent analogue of the potent delta-opioid receptor antagonist Dmt-Tic. J Med Chem. 2004 Dec 16;47(26):6541-6.
REF 4 Synthesis and in vitro biological evaluation of a carbon glycoside analogue of morphine-6-glucuronide. Bioorg Med Chem Lett. 2005 Mar 15;15(6):1583-6.
REF 5 From the potent and selective mu opioid receptor agonist H-Dmt-d-Arg-Phe-Lys-NH(2) to the potent delta antagonist H-Dmt-Tic-Phe-Lys(Z)-OH. J Med Chem. 2005 Aug 25;48(17):5608-11.
REF 6 New series of potent delta-opioid antagonists containing the H-Dmt-Tic-NH-hexyl-NH-R motif. Bioorg Med Chem Lett. 2005 Dec 15;15(24):5517-20.
REF 7 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists. Bioorg Med Chem Lett. 2006 Jan 1;16(1):146-9.
REF 8 Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists. J Med Chem. 2005 Dec 15;48(25):8035-44.
REF 9 Conversion of the potent delta-opioid agonist H-Dmt-Tic-NH-CH(2)-bid into delta-opioid antagonists by N(1)-benzimidazole alkylation(1). J Med Chem. 2005 Dec 29;48(26):8112-4.
REF 10 Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opio... J Med Chem. 2006 Jan 12;49(1):256-62.
REF 11 Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists. J Med Chem. 2006 Mar 9;49(5):1773-80.
REF 12 Conformational restriction of the phenylalanine residue in a cyclic opioid peptide analogue: effects on receptor selectivity and stereospecificity. J Med Chem. 1991 Oct;34(10):3125-32.
REF 13 Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3... Bioorg Med Chem Lett. 2006 Jul 15;16(14):3688-92.
REF 14 Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors. J Med Chem. 2006 May 18;49(10):2868-75.
REF 15 6-N,N-dimethylamino-2,3-naphthalimide: a new environment-sensitive fluorescent probe in delta- and mu-selective opioid peptides. J Med Chem. 2006 Jun 15;49(12):3653-8.
REF 16 New 2',6'-dimethyl-L-tyrosine (Dmt) opioid peptidomimetics based on the Aba-Gly scaffold. Development of unique mu-opioid receptor ligands. J Med Chem. 2006 Jun 29;49(13):3990-3.
REF 17 Discovery of novel triazole-based opioid receptor antagonists. J Med Chem. 2006 Jul 13;49(14):4044-7.
REF 18 Synthesis and evaluation of 3-aminopropionyl substituted fentanyl analogues for opioid activity. Bioorg Med Chem Lett. 2006 Sep 15;16(18):4946-50.
REF 19 Structural determinants of opioid activity in derivatives of 14-aminomorphinones: effect of substitution in the aromatic ring of cinnamoylaminomorp... J Med Chem. 2006 Aug 24;49(17):5333-8.
REF 20 Replacement of the N-terminal tyrosine residue in opioid peptides with 3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid (Dcp) results in novel opio... J Med Chem. 2006 Aug 24;49(17):5382-5.
REF 21 Highly potent and selective phenylmorphan-based inverse agonists of the opioid delta receptor. J Med Chem. 2006 Sep 7;49(18):5597-609.
REF 22 Effect of lysine at C-terminus of the Dmt-Tic opioid pharmacophore. J Med Chem. 2006 Sep 7;49(18):5610-7.
REF 23 New opioid designed multiple ligand from Dmt-Tic and morphinan pharmacophores. J Med Chem. 2006 Sep 7;49(18):5640-3.
REF 24 Grandisines C-G, indolizidine alkaloids from the Australian rainforest tree Elaeocarpus grandis. J Nat Prod. 2006 Sep;69(9):1295-9.
REF 25 Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization. Bioorg Med Chem. 2007 Feb 15;15(4):1694-702.
REF 26 Partial retro-inverso, retro, and inverso modifications of hydrazide linked bifunctional peptides for opioid and cholecystokinin (CCK) receptors. J Med Chem. 2007 Jan 11;50(1):165-8.
REF 27 Beta-methyl substitution of cyclohexylalanine in Dmt-Tic-Cha-Phe peptides results in highly potent delta opioid antagonists. J Med Chem. 2007 Jan 25;50(2):328-33.
REF 28 Synthesis and characterization of potent and selective mu-opioid receptor antagonists, [Dmt(1), D-2-Nal(4)]endomorphin-1 (Antanal-1) and [Dmt(1), D... J Med Chem. 2007 Feb 8;50(3):512-20.
REF 29 High-affinity carbamate analogues of morphinan at opioid receptors. Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11.
REF 30 Dicarba analogues of the cyclic enkephalin peptides H-Tyr-c[D-Cys-Gly-Phe-D(or L)-Cys]NH(2) retain high opioid activity. J Med Chem. 2007 Mar 22;50(6):1414-7.
REF 31 Further studies of tyrosine surrogates in opioid receptor peptide ligands. Bioorg Med Chem Lett. 2007 May 1;17(9):2656-60.
REF 32 Bioorg Med Chem Lett. 2007 Jun 1;17(11):3028-33. Epub 2007 Mar 21.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
REF 33 Bioorg Med Chem Lett. 2007 Jun 1;17(11):3023-7. Epub 2007 Mar 23.Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
REF 34 In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors. Bioorg Med Chem. 2007 Jun 15;15(12):4106-12.
REF 35 Indolizidine alkaloids with delta-opioid receptor binding affinity from the leaves of Elaeocarpus fuscoides. J Nat Prod. 2007 May;70(5):872-5.
REF 36 Bifunctional [2',6'-dimethyl-L-tyrosine1]endomorphin-2 analogues substituted at position 3 with alkylated phenylalanine derivatives yield potent mi... J Med Chem. 2007 Jun 14;50(12):2753-66.
REF 37 Design, synthesis, and biological evaluation of novel bifunctional C-terminal-modified peptides for delta/mu opioid receptor agonists and neurokini... J Med Chem. 2007 Jun 14;50(12):2779-86.
REF 38 Synthesis of stable and potent delta/mu opioid peptides: analogues of H-Tyr-c[D-Cys-Gly-Phe-D-Cys]-OH by ring-closing metathesis. J Med Chem. 2007 Jun 28;50(13):3138-42.
REF 39 Probes for narcotic receptor mediated phenomena. 34. Synthesis and structure-activity relationships of a potent mu-agonist delta-antagonist and an ... J Med Chem. 2007 Aug 9;50(16):3765-76.
REF 40 Structure-activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 1. Bioorg Med Chem Lett. 2007 Oct 1;17(19):5349-52.
REF 41 A new opioid designed multiple ligand derived from the micro opioid agonist endomorphin-2 and the delta opioid antagonist pharmacophore Dmt-Tic. Bioorg Med Chem. 2007 Nov 15;15(22):6876-81.
REF 42 Development of novel enkephalin analogues that have enhanced opioid activities at both mu and delta opioid receptors. J Med Chem. 2007 Nov 1;50(22):5528-32.
REF 43 Structure activity relationship studies of carboxamido-biaryl ethers as opioid receptor antagonists (OpRAs). Part 2. Bioorg Med Chem Lett. 2007 Dec 15;17(24):6841-6.
REF 44 Alkaloids with human delta-opioid receptor binding affinity from the Australian rainforest tree Peripentadenia mearsii. J Nat Prod. 2007 Dec;70(12):1946-50.
REF 45 Endomorphin-2 with a beta-turn backbone constraint retains the potent micro-opioid receptor agonist properties. J Med Chem. 2008 Jan 10;51(1):173-7.
REF 46 Novel coumarin glycoside and phenethyl vanillate from Notopterygium forbesii and their binding affinities for opioid and dopamine receptors. Bioorg Med Chem. 2008 Mar 15;16(6):3218-23.
REF 47 Role of benzimidazole (Bid) in the delta-opioid agonist pseudopeptide H-Dmt-Tic-NH-CH(2)-Bid (UFP-502). Bioorg Med Chem. 2008 Mar 15;16(6):3032-8.
REF 48 A structure-activity relationship study and combinatorial synthetic approach of C-terminal modified bifunctional peptides that are delta/mu opioid ... J Med Chem. 2008 Mar 13;51(5):1369-76.
REF 49 Blood-brain barrier penetration by two dermorphin tetrapeptide analogues: role of lipophilicity vs structural flexibility. J Med Chem. 2008 Apr 24;51(8):2571-4.
REF 50 Herkinorin analogues with differential beta-arrestin-2 interactions. J Med Chem. 2008 Apr 24;51(8):2421-31.
REF 51 Ligand binding to nucleic acids and proteins: Does selectivity increase with strength Eur J Med Chem. 2008 Nov;43(11):2307-15.
REF 52 Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 6: Opioid receptor binding properties of cyclic variants of 8-c... Bioorg Med Chem. 2008 May 15;16(10):5653-64.
REF 53 Structure-activity study of endomorphin-2 analogs with C-terminal modifications by NMR spectroscopy and molecular modeling. Bioorg Med Chem. 2008 Jun 15;16(12):6415-22.
REF 54 New endomorphin analogues containing alicyclic beta-amino acids: influence on bioactive conformation and pharmacological profile. J Med Chem. 2008 Jul 24;51(14):4270-9.
REF 55 Further studies on lead compounds containing the opioid pharmacophore Dmt-Tic. J Med Chem. 2008 Aug 28;51(16):5109-17.
REF 56 Potent, orally bioavailable delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-4-(5-hydroxyspiro[chromene-2,4'-pipe... J Med Chem. 2008 Oct 9;51(19):5893-6.
REF 57 Novel opioid peptide derived antagonists containing (2S)-2-methyl-3-(2,6-dimethyl-4-carbamoylphenyl)propanoic acid [(2S)-Mdcp]. J Med Chem. 2008 Sep 25;51(18):5866-70.
REF 58 The importance of micelle-bound states for the bioactivities of bifunctional peptide derivatives for delta/mu opioid receptor agonists and neurokin... J Med Chem. 2008 Oct 23;51(20):6334-47.
REF 59 Syntheses and opioid receptor binding properties of carboxamido-substituted opioids. Bioorg Med Chem Lett. 2009 Jan 1;19(1):203-8.
REF 60 Redefining the structure-activity relationships of 2,6-methano-3-benzazocines. Part 7: syntheses and opioid receptor properties of cyclic variants ... Bioorg Med Chem Lett. 2009 Jan 15;19(2):365-8.
REF 61 14 beta-O-cinnamoylnaltrexone and related dihydrocodeinones are mu opioid receptor partial agonists with predominant antagonist activity. J Med Chem. 2009 Mar 26;52(6):1553-7.
REF 62 Syntheses of novel high affinity ligands for opioid receptors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2289-94.
REF 63 The discovery of tropane derivatives as nociceptin receptor ligands for the management of cough and anxiety. Bioorg Med Chem Lett. 2009 May 1;19(9):2519-23.
REF 64 Design and synthesis of novel delta opioid receptor agonists and their pharmacologies. Bioorg Med Chem Lett. 2009 May 15;19(10):2792-5.
REF 65 Design, synthesis, and characterization of 6beta-naltrexol analogs, and their selectivity for in vitro opioid receptor subtypes. Bioorg Med Chem Lett. 2009 May 15;19(10):2811-4.
REF 66 Nascent structure-activity relationship study of a diastereomeric series of kappa opioid receptor antagonists derived from CJ-15,208. Bioorg Med Chem Lett. 2009 Jul 1;19(13):3647-50.
REF 67 Univalent and bivalent ligands of butorphan: characteristics of the linking chain determine the affinity and potency of such opioid ligands. J Med Chem. 2009 Dec 10;52(23):7389-96.
REF 68 Spirocyclic delta opioid receptor agonists for the treatment of pain: discovery of N,N-diethyl-3-hydroxy-4-(spiro[chromene-2,4'-piperidine]-4-yl) b... J Med Chem. 2009 Sep 24;52(18):5685-702.
REF 69 The biological activity and metabolic stability of peptidic bifunctional compounds that are opioid receptor agonists and neurokinin-1 receptor anta... Bioorg Med Chem. 2009 Oct 15;17(20):7337-43.
REF 70 The effects of C-terminal modifications on the opioid activity of [N-benzylTyr(1)]dynorphin A-(1-11) analogues. J Med Chem. 2009 Nov 12;52(21):6814-21.
REF 71 Agonist vs antagonist behavior of delta opioid peptides containing novel phenylalanine analogues in place of Tyr(1). J Med Chem. 2009 Nov 12;52(21):6941-5.
REF 72 14beta-Arylpropiolylamino-17-cyclopropylmethyl-7,8-dihydronormorphinones and related opioids. Further examples of pseudoirreversible mu opioid rece... J Med Chem. 2009 Nov 12;52(21):6926-30.
REF 73 Synthesis and opioid receptor binding affinities of 2-substituted and 3-aminomorphinans: ligands for mu, kappa, and delta opioid receptors. J Med Chem. 2010 Jan 14;53(1):402-18.
REF 74 Synthesis and evaluation of opioid receptor-binding affinity of elaeocarpenine and its analogs. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1601-3.
REF 75 Effect of linker substitution on the binding of butorphan univalent and bivalent ligands to opioid receptors. Bioorg Med Chem Lett. 2010 Mar 1;20(5):1507-9.
REF 76 Carba-analogues of fentanyl are opioid receptor agonists. J Med Chem. 2010 Apr 8;53(7):2875-81.
REF 77 Hasubanan alkaloids with delta-opioid binding affinity from the aerial parts of Stephania japonica. J Nat Prod. 2010 May 28;73(5):988-91.
REF 78 Role of 2',6'-dimethyl-l-tyrosine (Dmt) in some opioid lead compounds. Bioorg Med Chem. 2010 Aug 15;18(16):6024-30.
REF 79 Synthesis and activity of endomorphin-2 and morphiceptin analogues with proline surrogates in position 2. Eur J Med Chem. 2010 Oct;45(10):4594-600.
REF 80 SAR development of a series of 8-azabicyclo[3.2.1]octan-3-yloxy-benzamides as kappa opioid receptor antagonists. Part 2. Bioorg Med Chem Lett. 2010 Sep 15;20(18):5405-10.
REF 81 Design and synthesis of KNT-127, a -opioid receptor agonist effective by systemic administration. Bioorg Med Chem Lett. 2010 Nov 1;20(21):6302-5.
REF 82 Photoactivatable opiate derivatives as irreversible probes of the mu-opioid receptor. J Med Chem. 1990 Sep;33(9):2456-64.
REF 83 Design and synthesis of conformationally constrained somatostatin analogues with high potency and specificity for mu opioid receptors. J Med Chem. 1986 Nov;29(11):2370-5.
REF 84 Synthesis of analogues of acetylmethadol and methadol as potential narcotic antagonists. J Med Chem. 1981 Jul;24(7):903-6.
REF 85 Potential affinity labels for the opiate receptor based on fentanyl and related compounds. J Med Chem. 1982 Aug;25(8):913-9.
REF 86 Design and synthesis of highly potent and selective cyclic dynorphin A analogs. 2. New analogs. J Med Chem. 1993 Mar 19;36(6):750-7.
REF 87 Design of cyclic deltorphins and dermenkephalins with a disulfide bridge leads to analogues with high selectivity for delta-opioid receptors. J Med Chem. 1994 Jan 7;37(1):141-5.
REF 88 A topochemical approach to explain morphiceptin bioactivity. J Med Chem. 1993 Mar 19;36(6):708-19.
REF 89 Synthesis and pharmacological activity of deltorphin and dermorphin-related glycopeptides. J Med Chem. 1997 Aug 29;40(18):2948-52.
REF 90 Investigation of the N-substituent conformation governing potency and mu receptor subtype-selectivity in (+)-(3R, 4R)-dimethyl-4-(3-hydroxyphenyl)p... J Med Chem. 1998 May 21;41(11):1980-90.
REF 91 kappa-Opioid receptor effects of butorphanol in rhesus monkeys. J Pharmacol Exp Ther. 1999 Jul;290(1):259-65.
REF 92 Loperamide binding to opiate receptor sites of brain and myenteric plexus. J Pharmacol Exp Ther. 1976 Oct;199(1):131-40.
REF 93 Progress in developing cholecystokinin (CCK)/gastrin receptor ligands that have therapeutic potential. Curr Opin Pharmacol. 2007 Dec;7(6):583-92.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.